Temporary effects of circulating Amadori products on glomerular filtration properties in the normal mouse.
Previous studies have established a preferential glomerular filtration of glycated BSA (gBSA), as well as a facilitated filtration of BSA in the presence of gBSA. We intend to determine whether these modifications are permanent or transitory. gBSA was intravenously injected into anesthetized normal mice and maintained in circulation for 30 min, 1, 2, 24, and 48 h. Five minutes before death, FITC-BSA was injected. On immunocytochemical evaluations, increased glomerular filtration of FITC-BSA was found at all circulating time points. Changes at 24 and 48 h were less pronounced. Glomerular basement membrane (GBM)-to-lumen gBSA labeling ratios were similar at all time points suggesting no accumulation of gBSA in the GBM. Seventy percent of the gBSA was cleared from the circulation and the GBM after 24 h, and 95% after 48 h. This was confirmed in experiments with radiolabeled tracers. These results suggest that the alteration in GBM permeability to BSA in the normal mouse are due to the presence of gBSA and are gradually overcome along with its clearance from circulation. In early diabetes, increasing concentrations of circulating glycated proteins could be responsible for changes in glomerular permselectivity and probably for the alteration in glomerular filtration properties leading to diabetic nephropathy.
Londoño
I
I
Department of Pathology and Cell Biology, Université de Montréal, Montreal, Quebec, Canada H3C 3J7.
Bendayan
M
M
D000818:Animals; D001485:Basement Membrane / Q000502:physiology / Q000648:ultrastructure; D002196:Capillaries / Q000502:physiology; D004730:Endothelium, Vascular / Q000502:physiology / Q000648:ultrastructure; D016650:Fluorescein-5-isothiocyanate / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology*; D017127:Glycation End Products, Advanced; D006031:Glycosylation; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D007678:Kidney Glomerulus / Q000098:blood supply / Q000502:physiology* / Q000648:ultrastructure; D008297:Male; D051379:Mice; D012709:Serum Albumin / Q000493:pharmacokinetics / Q000494:pharmacology*; D012710:Serum Albumin, Bovine / Q000493:pharmacokinetics / Q000494:pharmacology*; D013997:Time Factors; D019459:Urothelium / Q000502:physiology / Q000648:ultrastructure; D000093423:Glycated Serum Albumin
D017127:Glycation End Products, Advanced; D007457:Iodine Radioisotopes; D012709:Serum Albumin; C039217:fluorescein isothiocyanate bovine serum albumin; D012710:Serum Albumin, Bovine; D016650:Fluorescein-5-isothiocyanate; D000093423:Glycated Serum Albumin